GHRH receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Alpha-synuclein has been shown to interact with Dopamine transporter, Parkin (ligase), Phospholipase D1, SNCAIP, Tau protein. Beta amyloid Synuclein Contursi Terme - the village in Italy where a mutation in the α-synuclein gene led to a family history of Parkinson's disease Anti-α-synuclein drug Media related to Alpha-synuclein at Wikimedia Commons alpha-Synuclein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human SNCA genome location and SNCA gene details page in the UCSC Genome Browser.
The calculations to be performed on the measurements taken depend on the technology used, since beta counters measure the sample's radioactivity whereas AMS determines the ratio of the three different carbon isotopes in the sample. To determine the age of a sample whose activity has been measured by beta counting, the ratio of its activity to the activity of the standard must be found. To determine this, a blank sample (of old, or dead, carbon) is measured, and a sample of known activity is measured. The additional samples allow errors such as background radiation and systematic errors in the laboratory setup to be detected and corrected for. The most common standard sample material is oxalic acid, such as the HOxII standard, 1,000 lb of which was prepared by the National Institute of Standards and Technology (NIST) in 1977 from French beet harvests. The results from AMS testing are in the form of ratios of 12C, 13C, and 14C, which are used to calculate Fm, the "fraction modern". This is defined as the ratio between the 14C/12C ratio in the sample and the 14C/12C ratio in modern carbon, which is in turn defined as the 14C/12C ratio that would have been measured in 1950 had there been no fossil fuel effect. Both beta counting and AMS results have to be corrected for fractionation. This is necessary because different materials of the same age, which because of fractionation have naturally different 14C/12C ratios, will appear to be of different ages because the 14C/12C ratio is taken as the indicator of age.
=== Lactase supplements === When lactose avoidance is not possible, or on occasions when a person chooses to consume such items, then enzymatic lactase supplements may be used. Lactase enzymes similar to those produced in the small intestines of humans are produced industrially by fungi of the genus Aspergillus. The enzyme, β-galactosidase, is available in tablet form in a variety of doses, in many countries without a prescription. It functions well only in high-acid environments, such as that found in the human gut due to the addition of gastric juices from the stomach. Unfortunately, too much acid can denature it, so it should not be taken on an empty stomach. Also, the enzyme is ineffective if it does not reach the small intestine by the time the problematic food does. Lactose-sensitive individuals can experiment with both timing and dosage to fit their particular needs. While essentially the same process as normal intestinal lactose digestion, direct treatment of milk employs a different variety of industrially produced lactase. This enzyme, produced by yeast from the genus Kluyveromyces, takes much longer to act, must be thoroughly mixed throughout the product, and is destroyed by even mildly acidic environments. Its main use is in producing the lactose-free or lactose-reduced dairy products sold in supermarkets.
Sources: en.wikipedia.org
== Prediction == Because viscosity depends continuously on temperature and pressure, it cannot be fully characterized by a finite number of experimental measurements. Predictive formulas become necessary if experimental values are not available at the temperatures and pressures of interest. This capability is important for thermophysical simulations, in which the temperature and pressure of a fluid can vary continuously with space and time. A similar situation is encountered for mixtures of pure fluids, where the viscosity depends continuously on the concentration ratios of the constituent fluids For the simplest fluids, such as dilute monatomic gases and their mixtures, ab initio quantum mechanical computations can accurately predict viscosity in terms of fundamental atomic constants, i.e., without reference to existing viscosity measurements. For the special case of dilute helium, uncertainties in the ab initio calculated viscosity are two order of magnitudes smaller than uncertainties in experimental values. For slightly more complex fluids and mixtures at moderate densities (i.e. sub-critical densities) Revised Enskog Theory can be used to predict viscosities with some accuracy. Revised Enskog Theory is predictive in the sense that predictions for viscosity can be obtained using parameters fitted to other, pure-fluid thermodynamic properties or transport properties, thus requiring no a priori experimental viscosity measurements. For most fluids, high-accuracy, first-principles computations are not feasible.
Mindlin (1928), engineer, Medal for Merit and ASME Medal recipient Harold Charles Bold (1929), botanist Jule Eisenbud (1929), psychiatrist known for research into parapsychology Theodore Lidz (1930), Sterling Professor of psychiatry at Yale; expert on schizophrenia Judd Marmor (1930), psychoanalyst and psychiatrist on homosexuality Herbert L. Anderson (1931), director of the Enrico Fermi Institute, professor of the University of Chicago Paul E. Queneau (1931), professor of metallurgical engineering at Dartmouth College Bernard Glueck Jr. (1933), psychiatrist, former president of the American Psychopathological Association Irving Kaplan (1933), chemist, professor at Massachusetts Institute of Technology Leo Rangell (1933), psychoanalyst; president of the International Psychoanalytical Association and the American Psychoanalytic Association John K. Lattimer (1935), urologist, ballistics expert, and inveterate collector Emanuel Papper (1935), anesthesiologist, dean of the Miller School of Medicine at the University of Miami 1969–1981 Norman Foster Ramsey Jr. (1935), winner of the Nobel Prize in Physics Robert Marshak (1936), president of the American Physical Society and president of the City College of New York Julian Schwinger (1936), winner of the Nobel Prize in Physics; posited the Schwinger effect Barry Commoner (1937), leading environmentalist, former editor of Science Illustrated magazine Francis J. Ryan (1937), professor of zoology at Columbia University Boris Jacobsohn (1938), professor of Physics at the University of Washington David B.
=== Clinical Laboratory Development Program === The work of SHIELD Illinois will continue through the Clinical Laboratory Development Program powered by SHIELD Illinois ("CLDP"). Utilizing the state-of-the-art laboratory renovated by SHIELD Illinois at the University of Illinois Chicago, CLDP will address the critical shortage of qualified clinical laboratory personnel in Illinois. The goal of the program is to develop the next generation of laboratory technicians and scientists through hands-on training and work experience.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.